{"id":"NCT00105079","sponsor":"Hoffmann-La Roche","briefTitle":"GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection","officialTitle":"A 48-week, Randomized, Open-label, 2-arm Study to Compare the Efficacy of Saquinavir/Ritonavir Twice Daily (BID) Plus Emtricitabine/Tenofovir Once Daily (QD) Versus Lopinavir/Ritonavir BID Plus Emtricitabine/Tenofovir QD in Treatment-na√Øve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients (GEMINI Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-04","primaryCompletion":"2007-08","completion":"2008-07","firstPosted":"2005-03-07","resultsPosted":"2011-11-02","lastUpdate":"2011-11-02"},"enrollment":337,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections"],"interventions":[{"type":"DRUG","name":"saquinavir [Invirase]","otherNames":["Invirase"]},{"type":"DRUG","name":"Lopinavir/ritonavir","otherNames":["Kaletra"]},{"type":"DRUG","name":"Emtricitabine/tenofovir disoproxil fumarate","otherNames":["Truvada"]},{"type":"DRUG","name":"Ritonavir","otherNames":["Norvir"]}],"arms":[{"label":"saquinavir/ritonavir","type":"EXPERIMENTAL"},{"label":"lopinavir/ritonavir","type":"ACTIVE_COMPARATOR"}],"summary":"This 2 arm study will evaluate the efficacy, safety and tolerability of saquinavir/ritonavir or lopinavir/ritonavir in combination with emtricitabine/tenofovir in patients with human immunodeficiency virus type 1 (HIV-1) infection who have received no prior HIV treatment. Patients will be randomized to receive either saquinavir/ritonavir 1000/100mg oral (po) twice daily (bid) + emtricitabine/tenofovir 200/300mg po once daily (qd), or lopinavir/ritonavir 400/100mg po bid + emtricitabine/tenofovir 200/300mg po qd. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Number of Patients With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) Viral Load <50 Copies/mL","timeFrame":"Week 48","effectByArm":[{"arm":"Saquinavir/Ritonavir","deltaMin":108,"sd":null},{"arm":"Lopinavir/Ritonavir","deltaMin":108,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":44,"countries":["United States","Canada","France","Puerto Rico","Thailand"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":163},"commonTop":["Diarrhoea","Nausea","Vomiting","Upper respiratory tract infection","Fatigue"]}}